NEWS CENTER

PRESS RELEASES

09.19.2021
EPIC SCIENCES COMPREHENSIVE CANCER PROFILING PLATFORM SHOWS COMPELLING VALUE OF CELL ANALYSIS IN DATA PRESENTED AT ESMO CONGRESS 2021
Epic Sciences, Inc.'s (Epic) Comprehensive Cancer Profiling™ Platform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate. Read Full Release
02.11.2021
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of Circulating Tumor Cell (CTC) Count at 2021 ASCO Genitourinary (GU) Cancers Symposium
Epic Sciences, Inc. announced today it will present two abstracts at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium virtual meeting on February 11 – 13, 2021. The abstracts feature analysis on the prognostic and predictive value of CTC enumeration in men with progressing mCRPC starting a standard-of-care therapy. Read Full Release
11.19.2020
Epic Sciences Enters into Exclusive Licensing Agreement and Collaboration with USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions. Read Full Release
10.29.2020
Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners
Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLASÔ, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw. Read Full Release

NEWS

05.02.2021 | Clinical OMICs
Shifting Paradigms in Precision Oncology
Epic Science’s core proprietary technology involves single-cell sequencing of circulating tumor cells (CTCs), but it uses ctDNA and white blood cells derived from a single blood draw in its work. Read Full Article
11.30.2020 | genomeweb
Epic Sciences, USC Michelson Center Sign Licensing Agreement for Liquid Biopsy Research

NEW YORK – Epic Sciences said on Thursday that it has signed a licensing agreement with the University of Southern California's Michelson Center for Convergent Bioscience to improve the firm's liquid biopsy platform and allow for more precise characterization of rare circulating tumor cells (CTCs).

As part of the collaboration, San Diego-based Epic will have access to the center's liquid biopsy samples and expand its platform to in-depth characterization of both cell-free fractions and CTCs using genomic, proteomic, and AI-based morphological tools. Read Full Article

11.09.2020 | Clinical OMICs
Companies are rapidly advancing liquid biopsies as the go-to technology for cancer treatment monitoring and recurrence
Liquid biopsies are becoming increasingly sensitive and personal thanks to advances in next-generation sequencing and target amplification. In addition, machine learning algorithms are being used on large datasets to characterize the molecular signatures of various cancer types. Read Full Article
05.28.2020 | Clinical OMICs
Comprehensive Approach - Epic Sciences has retooled its management team and is combining CTC and ctDNA technologies in its pursuit of comprehensive cancer profiling
In the realm of liquid biopsy as a tool for precision medicine and the different cells and fractions that can be collected from a standard blood draw, there has always been a sense that there is something missing. Circulating tumor cells (CTCs,) hard to collect, and even harder to collect as a viable cell, would never be the source of all the information needed to make a targeted cancer diagnosis. Read Full Article

EVENTS

ISLB 2020
The Epic Sciences team presented at the virtual ISLB 2020 Annual Congress Meeting - October 30, 2020. More Info
ASCO 2020
The Epic Sciences team will be presenting at the virtual ASCO 2020 Annual Meeting - From May 29 - 31, 2020. More Info
SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info